Background
- Recombinant proteins that bind to two different antigens, one of which activates T cells and the other binds a cancer target
- Used in treating some hematologic malignancies
Safety
Adverse Effects
- Some of the most serious adverse effects include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome
- Usually within days of first dose
- Causes hypogammaglobulinemia that can last months to years
- Most patients develop some neutropenia, which can last weeks
- Infections are common, mostly bacterial and viral and occasionally fungal
- Bacterial pneumonia is most common
- COVID-19, with prolonged course
- EBV and CMV, cases of JCV
Screening
- Consider baseline HIV, EBV, CMV, hepatitis B, and hepatitis C serologies
